Is Thymosin Alpha-1 Legal in Louisiana?

HealthRX.com

Federally, thymosin alpha-1 has no US approval

Print or save as PDF

  • FDA approval / Not approved; four US orphan drug designations are not approvals [1]
  • Pharmacy bulk-substance list / FDA proposed not to add it; committee voted 17 no, 4 yes [3]
  • State-licensed pharmacy list / In none of the three categories [2]
  • Outsourcing facility list / Category 3, nominated without adequate support [4]
  • Category 1 policy / Does not apply to thymosin alpha-1 [2]
  • Safety-risk table / Moved to 'nominated but withdrawn'; FDA concerns remain posted [5]
  • HHS peptide policy / Not one of the six peptides in the October 2026 draft [6]
  • Approved outside the US / Italy, India, Hong Kong [1]

Is thymosin alpha-1 FDA-approved?

No. A Drugs@FDA search found no US application for it [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US; it is not interchangeable with bulk thymosin alpha-1 powder [1].

Can a US pharmacy compound it?

On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, thymosin alpha-1 appears in none of the three categories [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is in category 3, 'nominated without adequate support' [4]. FDA's category 1 policy, under which the agency generally takes no action against compounders that meet its conditions, does not apply to it [2].

FDA proposed that the peptide not be added to the pharmacy bulk-substance list. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety, and some who voted yes said patients should have access [3]. It had been in category 2 (significant safety risks) and came off that list when the nominators withdrew, but FDA's concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [5]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, and no FDA or HHS action allowing its compounding is known [6].

What this means for Louisiana

The federal record covers FDA approval and compounding policy only. Whether a Louisiana pharmacy may compound thymosin alpha-1, or a Louisiana prescriber may order it, depends on state law that is not covered here.

Questions worth asking

Choose the questions you want to keep

Where is it approved, and is there a US dose?

FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

No US-approved dose exists [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. How did the advisory committee vote on adding thymosin alpha-1 to the pharmacy bulk-substance list?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in Louisiana?
Federally, it is not FDA-approved and is not covered by FDA's category 1 compounding policy [1][2]. Louisiana-specific rules are not covered on this page.
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for it, and the four US orphan drug designations noted in FDA's December 2024 review are not approvals [1].
Why did FDA propose not to add it to the pharmacy bulk-substance list?
On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 17 no and 4 yes on both the free base and the acetate, with members voting no citing a lack of compelling evidence of clinical effectiveness and safety [3]. FDA's posted concerns also include immunogenicity risk for certain routes of administration and peptide impurity and characterization problems [5].
Can a compounding pharmacy make thymosin alpha-1 under FDA's lists?
It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is category 3, nominated without adequate support, on the outsourcing facility list [2][4].
What dose is approved in the US?
None. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 [1].
Show all 6 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Louisiana?